• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Response to "Men and women show similar survival rates after breast cancer", Yin Pan, Ze-Zhou Song.

作者信息

Thuler Luiz Claudio Santos, Bergmann Anke, Bender Paulo Franscisco Mascarenhas, de Oliveira Letícia Lima, Costa Célia Regina, de Aguiar Suzana Sales

机构信息

Brazilian National Cancer Institute (INCA), Rio de Janeiro, Brazil.

Federal University of Rio de Janeiro State (UNIRIO), Rio de Janeiro, Brazil.

出版信息

J Cancer Res Clin Oncol. 2017 Aug;143(8):1623-1625. doi: 10.1007/s00432-017-2447-x. Epub 2017 Jun 15.

DOI:10.1007/s00432-017-2447-x
PMID:28620684
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11819114/
Abstract
摘要

相似文献

1
Response to "Men and women show similar survival rates after breast cancer", Yin Pan, Ze-Zhou Song.对《男性和女性乳腺癌后的生存率相似》的回应，尹盼，宋泽洲
J Cancer Res Clin Oncol. 2017 Aug;143(8):1623-1625. doi: 10.1007/s00432-017-2447-x. Epub 2017 Jun 15.
2
Men and women show similar survival rates after breast cancer.乳腺癌患者中男性和女性的生存率相似。
J Cancer Res Clin Oncol. 2017 Apr;143(4):563-571. doi: 10.1007/s00432-016-2311-4. Epub 2016 Dec 8.
3
Commentary on: Men and women show similar survival rates after breast cancer.
J Cancer Res Clin Oncol. 2017 Aug;143(8):1621. doi: 10.1007/s00432-017-2443-1. Epub 2017 Jun 8.
4
Platinum-containing regimens for metastatic breast cancer.转移性乳腺癌的含铂方案。
Cochrane Database Syst Rev. 2017 Jun 23;6(6):CD003374. doi: 10.1002/14651858.CD003374.pub4.
5
Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.芳香化酶抑制剂用于治疗绝经后妇女的晚期乳腺癌。
Cochrane Database Syst Rev. 2007 Jan 24(1):CD003370. doi: 10.1002/14651858.CD003370.pub2.
6
Single agent versus combination chemotherapy for metastatic breast cancer.转移性乳腺癌的单药化疗与联合化疗
Cochrane Database Syst Rev. 2005 Apr 18(2):CD003372. doi: 10.1002/14651858.CD003372.pub2.
7
Clinical, therapeutic and prognostic differences between male and female patients with breast cancer-a comparison of 2510 men and 307,634 women in a registry-based study in Germany.德国一项基于登记处研究中2510名男性与307634名女性乳腺癌患者的临床、治疗及预后差异比较
J Cancer Res Clin Oncol. 2025 Jun 3;151(6):181. doi: 10.1007/s00432-025-06220-y.
8
Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.用于治疗绝经后女性晚期乳腺癌的芳香化酶抑制剂
Cochrane Database Syst Rev. 2009 Oct 7;2009(4):CD003370. doi: 10.1002/14651858.CD003370.pub3.
9
Single agent versus combination chemotherapy for metastatic breast cancer.转移性乳腺癌的单药化疗与联合化疗
Cochrane Database Syst Rev. 2009 Apr 15;2009(2):CD003372. doi: 10.1002/14651858.CD003372.pub3.
10
Platinum containing regimens for metastatic breast cancer.用于转移性乳腺癌的含铂方案。
Cochrane Database Syst Rev. 2004(2):CD003374. doi: 10.1002/14651858.CD003374.pub2.

本文引用的文献

1
Male breast cancer, clinical presentation, diagnosis and treatment: Twenty years of experience in our Breast Unit.男性乳腺癌：临床表现、诊断与治疗——我们乳腺科二十年的经验
Int J Surg Case Rep. 2016;20S(Suppl):8-11. doi: 10.1016/j.ijscr.2016.02.004. Epub 2016 Feb 26.
2
Male breast cancer: clinical-epidemiological characteristics of 1189 Brazilian patients.男性乳腺癌：1189例巴西患者的临床流行病学特征
Aging Male. 2015 Jun;18(2):118-23. doi: 10.3109/13685538.2014.922532. Epub 2014 May 28.
3
Chinese female breast cancer patients show a better overall survival than their male counterparts.中国女性乳腺癌患者的总生存情况优于男性患者。
Chin Med J (Engl). 2010 Sep;123(17):2347-52.
4
Defining menopausal status in epidemiologic studies: A comparison of multiple approaches and their effects on breast cancer rates.绝经状态在流行病学研究中的定义：多种方法的比较及其对乳腺癌发病率的影响。
Maturitas. 2010 Sep;67(1):60-6. doi: 10.1016/j.maturitas.2010.04.015. Epub 2010 May 21.
5
Male breast cancer.男性乳腺癌
Lancet. 2006 Feb 18;367(9510):595-604. doi: 10.1016/S0140-6736(06)68226-3.